Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
psoriasis
Biotech
Lilly changes lead psoriasis program from $2.4B Dice buyout
Lilly kicked DC-806 to the curb as part of a third-quarter cull that also affected the PD-1 autoimmune prospect peresolimab.
Nick Paul Taylor
Oct 30, 2024 10:00am
Awaiting regulator verdict, Innovent posts latest psoriasis win
Oct 29, 2024 9:50am
InnoCare's TYK2 inhibitor holds its own in ph. 2 psoriasis trial
Oct 9, 2024 9:10am
Ventyx's last hope for inflammatory med ends in Crohn's failure
Jul 29, 2024 9:45am
Alumis downsizes IPO, tacks on private placement
Jun 28, 2024 5:02am
Alumis eyes $300M IPO to fund clinical-stage TYK2 pipeline
Jun 24, 2024 8:14am